 |  |  |
|---|---|---|
 |  |  |
 |  |  |
 |  |  |
With 27 years of experience in conducting HIV research including HIV vaccine, HIV biomedical prevention
and treatment in various populations to develop academic knowledge on HIV / AIDS,
we have worked in collaboration with leading international research networks and other domestic agencies.
Our diverse research programs are up-to-date with present situation and necessity of knowledge both nationally and globally
We are ready to expand our field of expertise to other challenging infectious diseases and substance use
News and Activities
To find more information, click the image
November 02, 2020
Welcome new collaborative research teams from the C-free project, Raks Thai Foundation, Thai Drug Users' Network and Ozone Foundation at the site initiation meeting at RIHES main buildingOctober 08 and October 22, 2020
The HPTN 083 study team visited the Caremat Health Center and Mplus foundation, community based organizations actively working on HIV prevention for MSMs/TGs and adolescentsSurvey Results
Online Alcohol Sales during COVID-19 pandemicSeptember 28 -29, 2020
Knowledge Sharing Meeting: Exploratory and Qualitative Research in Hard-to-Reach Populations in Songkhla ProvinceAugust 26 -28, 2020
Dr. Arunrat Tangmunkongvorakul, as a speaker for a training “How to Conduct Qualitative Research in HIV and Other Health Priorities” at Thai Red Cross AIDS Research Center, BangkokAugust 14, 2020
"Chang for Life" project organized by Gang SAA at the children and youth training center Region 7, Chiang MaiJuly 24, 2020
Community Relation Unit newsletter July-September 2020 has been issued. Click the image to read moreResearch report
HIV Integrated Behavioral and Biological Surveillance Surveys Among People Who Inject Drugs:Chiang Mai, Thailand-2019Survey Results
Illegal Liqour in Thai SocietyResearch Studies Currently Underway
To learn more, click Study title (to visit webpage) or Study snapshot (in Thai)
Contact Us
Research Institute for Health Sciences, Chiang Mai University
110 Intavaroros Road, Sriphum, Muang
Chiang Mai 50200 THAILAND
Tel. 66 5393 6148
The purpose of this study is to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are naïve to HBV vaccination.
Study vaccines: HEPLISAV-B vs. Engerix-B
What the body of children under 12 years of age living with HIV do to these drugs?
Are they safe for this population?
Abacavir/Dolutegravir/Lamivudine Dispersible and
Abacavir/Dolutegravir/Lamivudine Immediate Release Tablets
A unique regimen containing two
anti-retroviral drugs that might avoid toxicities by minimizing the number of antiretrovirals without sacrificing long-term antiviral efficacy
This study is designed to evaluate the efficacy and safety of DTG/3TC as a FDC, in ART-naive HIV-1-infected adolescents, who weigh at least 25 kilograms (kg).